The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
Pharmaceutical Technology1d
Tirzepatide outpacing Wegovy in the obesity space
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...
Yahoo News10d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...
Yahoo10d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...
Everyday Health11d
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
National Institute for Health and Care Excellence12d
Tirzepatide for managing overweight and obesity
leading to inequality of access and patient outcomes services that already exist would need to be decommissioned to provide the resources required to deliver tirzepatide. Budget impact: The ...